These include type 2 diabetes and prediabetes (because GLP-1 medications affect blood sugar), thyroid conditions (because of the boxed warning about medullary thyroid carcinoma), a history of pancreatitis (because GLP-1 medications carry a small risk of pancreatitis), gastroparesis or other gastric motility disorders (because GLP-1 medications slow gastric emptying), and any history of eating disorders (because the appetite-suppressing effects of GLP-1 medications require careful management in patients with disordered eating)
This is not a beginner stack
Semaglutide, manufactured by Novo Nordisk and sold under the brands Ozempic and Wegovy, as treatment for type 2 diabetes (T2D) and obesity, respectively, was one of the catalysts behind the growth of the GLP-1RA market
The bridge program explicitly lifts the anti-obesity medication exclusion for qualifying patients
When diagnoses rise shortly after starting a medication, that pattern often reflects finding something that was already there, said co-author Rashmi Roy, in a statement from the center
H.MaJ.WilkinsonP.et al (1998)
-1.jpg&w=3840&q=75)
